Filing Flows › Steris (STE) › Guidance & outlook
Steris (STE) guidance and outlook
Steris (STE) raised its guidance on Nov 4, 2026: Revenue +7% to +8% for FY2027; EPS $11.35–$11.55 for FY2027; EPS $8.92–$9.12 for FY2027. Steris' 10-Q filed Nov 5, 2026 makes 17 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2027 | +7% to +8% | reaffirmed |
| Revenue | FY2027 | +6% to +7% | reaffirmed |
| EPS | FY2027 | $11.35–$11.55 | raised |
| EPS | FY2027 | $8.92–$9.12 | reaffirmed |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We expect to close the Xodus Medical Acquisition by December 31, 2026, subject to customary closing conditions and regulatory approvals.
- On August 5, 2026, the Company announced a targeted restructuring plan (the "Fiscal 2027 Manufacturing Restructuring Plan") to consolidate manufacturing and distribution for formulated chemistries to a new Center of Excellence in North Carolina.
- The investment is expected to accelerate innovation, expand capacity and optimize our U.S. chemistries manufacturing and distribution network.
- The Company currently expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges.
- Also during the second quarter of fiscal 2027, the Company approved an additional targeted restructuring plan (the "Fiscal 2027 Portfolio and Organizational Optimization Plan").
- The Company anticipates total charges of approximately $45 million associated with the plan, including approximately $10 million in cash expenditures and $35 million in non-cash charges.
- In May 2024, we adopted and announced a targeted restructuring plan (the "Fiscal 2025 Plan").
- In connection with the open restructuring plans, we expect to incur approximately $50 million to $60 million of cash expenditures, which are expected to be incurred over time and be substantially completed by fiscal 2030.
- We intend to use our existing cash and cash equivalent balances and cash generated from operations for short-term and long-term capital expenditures and our other liquidity needs.
- obtaining adequate manufacturing capacities, the timing and extent of our research and development projects, changes in our expenses and other factors.
- There can be no assurance that our existing financing arrangements will provide us with sufficient funds or that we will be able to obtain any additional funds on terms favorable to us or at all.
- We expect to fund the purchase price of the Xodus Medical Acquisition with a combination of approximately $2.0 billion of new debt, including approximately $500.0 million of borrowings under the Delayed Draw Term Loan, and cash on hand.
Steris' latest quarter
Steris, Q2 FY27: revenue $1.6B (+9% year over year), operating margin 18.5%, net earnings $214M, operating cash flow $289M. The chart follows the revenue to costs, profit and cash.
Questions
Did Steris raise or lower its guidance?
Steris (STE) raised its guidance on Nov 4, 2026: Revenue +7% to +8% for FY2027; EPS $11.35–$11.55 for FY2027; EPS $8.92–$9.12 for FY2027.
What does Steris expect?
We expect to close the Xodus Medical Acquisition by December 31, 2026, subject to customary closing conditions and regulatory approvals. On August 5, 2026, the Company announced a targeted restructuring plan (the "Fiscal 2027 Manufacturing Restructuring Plan") to consolidate manufacturing and distribution for formulated chemistries to a new Center of Excellence in North Carolina. The investment is expected to accelerate innovation, expand capacity and optimize our U.S. chemistries manufacturing and distribution network.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.